MMALM

MMALM
Clinical data
Other names4-Methallyloxy-2,5-dimethoxyamphetamine; 2,5-Dimethoxy-4-methallyloxyamphetamine
Drug classSerotonin 5-HT2 receptor agonist
ATC code
  • None
Identifiers
  • 1-{2,5-dimethoxy-4-[(2-methylprop-2-en-1-yl)oxy]phenyl}propan-2-amine
Chemical and physical data
FormulaC15H23NO3
Molar mass265.353 g·mol−1
3D model (JSmol)
  • COc1cc(CC(N)C)c(cc1OCC(=C)C)OC
  • InChI=1S/C15H23NO3/c1-10(2)9-19-15-8-13(17-4)12(6-11(3)16)7-14(15)18-5/h7-8,11H,1,6,9,16H2,2-5H3
  • Key:FKOOHEYOIKURNB-UHFFFAOYSA-N

MMALM, also known as 4-methallyloxy-2,5-dimethoxyamphetamine, is a serotonin receptor modulator of the phenethylamine, amphetamine, and DOx families. It is a derivative of the DOx psychedelics TMA-2 and MEM in which the 4-position substituent has been extended. The drug is also the α-methyl or amphetamine analogue of 2C-O-3.

Use and effects

The properties and effects of MMALM in humans do not appear to be known.

Pharmacology

Pharmacodynamics

MMALM acts as a potent agonist of the serotonin 5-HT2 receptors. Its affinities (Ki) were 61 nM for the serotonin 5-HT2A receptor and 290 nM for the serotonin 5-HT2C receptor, whereas its activational potencies (EC50Tooltip half-maximal effective concentration (EmaxTooltip maximal efficacy)) were 1.5 nM (95%) at the serotonin 5-HT2A receptor and 29 nM (90%) at the serotonin 5-HT2B receptor. Besides the serotonin 5-HT2 receptors, the drug showed little to no activity at various other assessed targets, such as the monoamine transporters. It does not appear to have been tested for psychedelic-like activity in animals.

History

MMALM was first described in the scientific literature by Daniel Trachsel in 2013. Subsequently, it was characterized in more detail by a group including Trachsel and Matthias Liechti in 2019. The compound's name is said to derive from its benzene ring substituents, "methoxy methallyloxy methoxy".

Society and culture

Canada

MMALM is a controlled substance in Canada under phenethylamine blanket-ban language.

See also